GH Research PLC
GHRS
查看详细走势图
12.785USD
+0.035+0.27%
收盘 12/24, 13:00（美东）报价延迟15分钟
793.05M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.27%
5天
+0.75%
1月
-12.31%
6月
+1.95%
今年开始到现在
+82.64%
1年
+80.32%
查看详细走势图
TradingKey GH Research PLC股票评分
单位: USD 更新时间: 2025-10-27操作建议
当前估值低估，机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价max_target_price。目前股价在压力位和支撑位之间，可以做区间波段操作。
GH Research PLC评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
买入
评级
30.375
目标均价
+107.62%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
GH Research PLC亮点
亮点风险
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-19.43，处于3年历史低位
机构减仓
最新机构持股43.68M股，环比减少2.83%
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓，最新持仓市值0.00
GH Research PLC新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
GH Research PLC简介
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
公司代码GHRS
公司GH Research PLC
CEOValcheva (Velichka)
网址
常见问题
GH Research PLC(GHRS)的当前股价是多少？
GH Research PLC(GHRS)的当前股价是 12.785。
GH Research PLC的股票代码是什么？
GH Research PLC的股票代码是GHRS。
GH Research PLC股票的52周最高点是多少？
GH Research PLC股票的52周最高点是20.500。
GH Research PLC股票的52周最低点是多少？
GH Research PLC股票的52周最低点是6.850。
GH Research PLC的市值是多少？
GH Research PLC的市值是793.05M。
GH Research PLC的净利润是多少？
GH Research PLC的净利润为-38.96M。
现在GH Research PLC(GHRS)的股票是买入、持有还是卖出？
根据分析师评级，GH Research PLC(GHRS)的总体评级为买入，目标价格为30.375。
GH Research PLC(GHRS)股票的每股收益（EPS TTM）是多少
GH Research PLC(GHRS)股票的每股收益（EPS TTM）是-0.731。
相关品种
